histori
outbreak
decemb
wuhan
health
commiss
hubei
provinc
republ
china
notifi
nation
health
commiss
china
cdc
cluster
case
pneumonia
unknown
etiolog
patient
present
constel
symptom
fever
dyspnea
dri
cough
radiolog
find
show
bilater
lung
glassi
opac
furthermor
public
health
offic
trace
case
huanan
seafood
wholesal
market
trade
live
speci
bat
snake
pangolin
badger
multipl
intrins
variabl
led
rapid
earli
transmiss
dynam
made
wuhan
flashpoint
pandem
wuhan
document
popul
million
made
wuhan
one
top
five
popul
citi
china
wuhan
larg
popul
densiti
proxim
marketplac
sold
live
anim
made
epicent
humananim
interfac
addit
lack
earli
contain
due
inabl
accur
trace
histori
exposur
earli
patient
case
contribut
rapid
rate
spread
wuhan
eventu
precipit
declar
viral
pneumonia
outbreak
januari
march
due
global
logarithm
expans
case
coronaviru
diseas
declar
pandem
virolog
januari
china
cdc
discov
viru
call
novel
coronaviru
colloqui
note
wuhan
coronaviru
renam
destigmat
associ
viru
geograph
locat
nation
relat
diseas
symptomatolog
viru
genet
similar
sar
coronaviru
myriad
coronavirus
caus
common
cold
coronavirus
becom
infect
attain
anim
reservoir
provid
adequ
cellular
environ
wherein
viru
multipli
acquir
seri
advantag
genet
mutat
mutat
enabl
viru
crossspeci
infect
multipli
within
human
host
effect
virion
structur
pathophysiolog
infect
beta
coronaviru
famili
positivesens
singlestrand
rna
envelop
viru
nm
diamet
genom
rna
kb
one
vital
encod
structur
protein
spike
glycoprotein
consist
three
heterodim
bind
angiotensinconvert
enzym
receptor
type
ii
pneumocyt
surfac
protein
hemagglutininesteras
dimer
shown
figur
entri
type
ii
pneumocyt
via
endocytosi
multipli
cytoplasm
high
protein
manufactur
stress
induc
upon
type
ii
pneumocyt
lead
apoptosi
addit
rna
act
pathogenassoci
molecular
pattern
pamp
recogn
pattern
recognit
receptor
tolllik
receptor
lead
chemokin
surg
caus
neutrophil
migrat
activ
lead
destruct
alveolarcapillari
wall
microscop
level
lead
loss
interfac
intraalveolar
space
surround
stroma
therefor
fluid
leak
fill
alveolar
sac
origin
origin
genom
link
bat
akin
merscov
virus
interestingli
wholegenom
align
genom
virus
batcov
batcov
rhinolophu
affini
speci
yunnan
provinc
similar
seen
previous
merscov
virus
undertak
resid
intermedi
host
shown
figur
suspect
pangolin
natur
reservoir
base
analysi
genom
contig
align
like
cov
renam
pangolincov
harbor
lung
tissu
two
dead
malayan
pangolin
pangolincov
whole
genom
similar
similar
batcov
proteom
analysi
reveal
subunit
spike
glycoprotein
close
relat
compar
batcov
furthermor
five
amino
acid
residu
protein
interact
receptor
ident
pangolincov
contrastingli
four
amino
acid
residu
ident
protein
batcov
interestingli
pangolincov
batcov
lost
furin
recognit
motif
vital
cleavag
put
furin
recognit
sequenc
still
intact
within
compil
find
portray
pangolin
intermedi
host
evolut
phylogenet
analysi
tang
et
al
genom
indic
two
major
lineag
coexist
lineag
design
ltype
codon
leucin
stype
codon
serin
defin
signific
linkag
lod
snp
posit
synonym
furthermor
stype
n
indic
ancestr
strain
attain
singlenucleotid
polymorph
snp
led
format
ltype
n
result
amino
acid
snp
open
read
frame
undefin
function
role
life
cycl
virul
therefor
tang
et
al
initi
label
ltype
aggress
lineag
base
higher
frequenc
mislead
aggress
lineag
label
remov
current
addendum
ltype
defin
higher
frequenc
must
note
frequenc
stype
ltype
correspond
patient
wuhan
moreov
although
stype
ancestr
lineag
surpris
major
earli
case
wuhan
ltype
lineag
global
stype
promin
one
patient
gisaid
id
usa
test
posit
coinfect
stype
ltype
unclear
caus
signific
clinic
sever
due
coinfect
also
notabl
current
evid
indic
immun
one
lineag
provid
crossreact
lineag
impli
patient
recov
one
lineag
sustain
anoth
separ
infect
strain
therefor
futur
vaccin
must
target
conserv
region
lineag
altern
separ
vaccin
lineag
must
design
mode
transmiss
mode
transmiss
trace
import
case
droplet
transmiss
fecalor
rout
conjunctiva
fomit
addit
local
transmiss
trace
back
patient
bodili
fluid
respiratori
droplet
saliva
fece
urin
virion
stabil
lower
temperatur
ie
higher
surviv
virion
shed
throughout
clinic
cours
patient
spread
infect
prior
symptom
present
symptomat
cours
clinic
recoveri
period
addit
consider
must
made
regard
resid
time
virion
surfac
halflif
aerosol
copper
cardboard
stainless
steel
plastic
h
h
h
h
h
respect
viabl
resid
time
aerosol
copper
cardboard
stainless
steel
plastic
h
h
h
h
h
respect
differ
common
cold
flu
common
cold
caus
myriad
virus
major
rhinovirus
benign
form
coronavirus
common
cold
gradual
cours
symptom
present
comparison
flu
caus
variou
strain
influenza
orthomyxoviru
famili
pyrexia
rare
common
cold
notabl
symptom
flu
present
cough
fatigu
rare
common
cold
coryz
symptom
rhinorrhea
nasal
congest
predomin
common
cold
rare
flu
present
similar
influenza
flu
diseas
respiratori
system
diseas
clinic
present
vari
asymptomat
sever
pneumonia
furthermor
influenza
transmit
contact
droplet
fomit
therefor
similar
hand
hygien
techniqu
respiratori
etiquett
benefici
prevent
spread
anoth
factor
influenc
rate
spread
infect
basic
reproduct
number
influenza
viru
wherea
viru
therefor
patient
spread
new
contact
compar
influenza
patient
comparison
sar
caus
viru
patient
caus
viru
infecti
incub
period
even
asymptomat
stage
time
elaps
advent
exposur
pathogen
clinic
manifest
diseas
term
incub
period
tabl
show
varianc
incub
period
coronaviru
common
orthomyxoviru
larger
incub
manifest
covid
along
abil
transmit
infect
period
explain
rapid
potenti
spread
clinic
present
infect
caus
viru
term
coronaviru
diseas
symptomatolog
extens
discuss
whochina
joint
report
n
patient
present
pyrexia
case
ill
cours
febril
earli
present
moreov
cough
seen
patient
sputum
produc
respiratori
symptom
dyspnea
sore
throat
nasal
congest
present
case
respect
constitut
symptom
muscl
bone
ach
chill
headach
seen
case
respect
gastrointestin
gi
symptom
nausea
vomit
diarrhea
seen
case
respect
clinic
manifest
consist
similar
studi
patient
china
n
n
n
n
sever
insult
lung
tissu
result
acut
respiratori
distress
syndrom
ard
precipit
septic
shock
two
complic
major
contributor
intens
care
unit
icu
care
mortal
patient
older
year
smoke
histori
comorbid
medic
condit
smoke
older
age
group
patient
tend
higher
densiti
receptor
list
chronic
medic
condit
affect
clinic
cours
summar
tabl
overal
analysi
n
show
lead
comorbid
condit
includ
hypertens
cardiovascular
cerebrovascular
diseas
diabet
largest
studi
n
median
age
patient
year
present
predominantli
mild
asymptomat
age
group
explan
phenomenon
yet
perhap
receptor
highli
express
age
group
preliminari
unpublish
singlecel
transcriptom
studi
suggest
asian
cell
donor
higher
receptor
densiti
caucasian
african
american
donor
varianc
distribut
could
explain
higher
suscept
asian
popul
viru
clinic
diseas
cours
offici
incub
period
day
therefor
day
chosen
cutoff
selfquarantin
guan
et
al
n
estim
mean
incub
period
three
day
ci
day
patient
develop
ill
onset
within
day
outlier
case
found
wherein
incub
period
day
wang
et
al
n
show
median
time
preliminari
symptom
dyspnea
hospit
admiss
ard
day
respect
median
hospit
stay
day
patient
discharg
figur
show
comprehens
summari
clinic
cours
patient
n
stratifi
base
survivor
nonsurvivor
zhou
et
al
show
survivor
group
develop
ard
sepsi
day
respect
convers
nonsurvivor
group
develop
ard
sepsi
later
day
respect
furthermor
nonsurvivor
group
develop
complic
acut
kidney
injuri
aki
secondari
infect
day
respect
lastli
survivor
group
discharg
hospit
day
nonsurvivor
group
die
day
epidemiolog
march
case
recov
die
therefor
worldwid
case
fatal
rate
cfr
within
time
period
current
estim
interpret
everi
case
spread
two
three
new
peopl
tabl
show
comparison
epidemiolog
paramet
major
infecti
outbreak
shown
figur
total
countri
territori
along
diamond
princess
cruis
ship
current
harbor
japan
affect
major
cluster
activ
case
usa
itali
spain
germani
franc
countri
highest
mortal
rate
itali
spain
iran
franc
usa
mortal
rate
increas
year
cohort
comparison
patient
year
old
mortal
rate
predilect
male
gender
f
furthermor
mortal
rate
also
increas
patient
addit
comorbid
cardiovascular
diabet
hypertens
lead
cohort
mortal
rate
respect
screen
tool
two
promin
screen
tool
one
develop
cdc
criteria
chart
evolv
progress
outbreak
tabl
updat
screen
tool
develop
cdc
diagnost
tool
januari
china
cdc
share
genet
sequenc
enabl
countri
develop
primer
genom
util
revers
transcriptas
polymeras
chain
reaction
rtpcr
assay
make
diagnosi
therefor
rtpcr
becom
gold
standard
diagnosi
sensit
essenti
mean
patient
would
test
neg
despit
infect
varianc
sensit
attribut
patient
test
earli
diseas
cours
wherein
viral
load
beneath
detect
level
due
lack
autom
sampl
prepar
rtpcr
furthermor
singl
neg
rtpcr
rule
henc
repeat
rtpcr
must
perform
concern
rise
regard
timefram
repeat
rtpcr
ideal
window
lie
hour
neg
test
largest
studi
n
show
ctchest
sensit
make
earli
diagnosi
identif
groundglass
opac
interpret
five
test
fals
rule
find
also
consist
case
seri
patient
wherein
sensit
ct
rtpcr
p
patient
investig
imag
assay
within
three
day
admiss
util
ct
scan
would
prevent
infect
patient
discharg
back
commun
con
increas
ct
usag
huge
econom
burden
healthcar
resourc
potenti
contamin
ct
scanner
manag
algorithm
ct
radiolog
use
stratifi
patient
requir
investig
isol
util
radiolog
direct
manag
plan
hospit
eas
access
ct
radiolog
lack
access
laboratori
servic
countri
util
central
laboratori
servic
larg
turnaround
time
contrastingli
chest
xray
poor
sensit
groundglass
opac
patient
must
isol
pathophysiolog
radiolog
find
viru
induc
inflammatori
respons
alveolar
sac
lead
accumul
exud
fluid
sever
progress
diseas
move
lobe
radiolog
find
solid
white
consolid
laboratori
examin
standard
blood
investig
reveal
patient
normal
decreas
leucocyt
lymphocytopenia
furthermor
system
elev
pyrogen
cytokin
critic
patient
neutrophilia
elev
ddimer
increas
plasma
blood
urea
nitrogen
bun
creatinin
also
document
patient
admit
icu
also
elev
plasma
level
interleukin
chemokin
granulocyt
coloni
stimul
factor
kd
monocyt
chemoattract
macrophag
inflammatori
protein
manag
manag
viral
pneumonia
predominantli
support
amidst
absenc
valid
antivir
drug
primari
symptom
manag
fever
nonproduct
cough
therefor
firstlin
antipyret
agent
paracetamol
antituss
choic
guaifenesin
supplementari
oxygen
lmin
must
administ
patient
requir
manag
sever
respiratori
distress
oxygen
satur
target
must
pregnant
patient
patient
complic
septic
shock
aki
manag
sepsi
protocol
renal
replac
therapi
rrt
respect
renal
function
test
fluid
balanc
measur
enabl
identif
patient
indic
rrt
patient
may
develop
superimpos
bacteri
fungal
infect
middl
later
cours
appropri
empir
antimicrobi
coverag
must
provid
latest
version
edit
guidelin
prevent
diagnosi
treatment
nation
health
commiss
nhc
china
recommend
combin
regimen
proteas
inhibitor
lopinavir
ritonavir
rational
combin
treatment
base
experi
regimen
reduc
mortal
rate
sar
recommend
usag
extracorpor
membran
oxygen
ecmo
patient
sustain
hypoxia
refractori
supplementari
oxygen
altern
convalesc
plasma
igg
use
rescu
therapi
critic
case
robust
evid
practic
major
case
public
health
measur
vital
manag
spread
public
health
measur
contain
adequ
patient
burden
supersed
capac
avail
icu
bed
mechan
ventil
seen
crisi
take
place
itali
therefor
entir
object
manag
rest
premis
social
distanc
suppress
rapid
emerg
influx
new
case
short
time
frame
epidemiolog
concept
refer
flatten
curv
mainstay
public
health
must
identifi
infect
case
isol
case
attain
contact
trace
isol
contact
present
symptom
discharg
criteria
quarantin
discontinu
four
major
discharg
criteria
exist
itali
ministero
della
salut
consiglio
superior
di
china
china
cdc
usa
cdc
singapor
nation
centr
infecti
diseas
model
differ
cutoff
china
cdc
discharg
criteria
state
four
condit
must
met
satisfi
discharg
hospit
patient
must
remain
apyrex
least
three
consecut
day
respiratori
symptom
cough
dyspnea
sore
throat
nasal
congest
must
resolv
chest
ct
must
demonstr
mark
resolut
exud
lesion
two
serial
rtpcr
must
neg
rna
nasopharyng
collect
assay
must
space
hour
quarantin
discontinu
criteria
two
separ
quarantin
discontinu
criteria
covid
patient
selfquarantin
home
develop
itali
ministero
della
salut
consiglio
superior
di
usa
cdc
cdc
quarantin
discontinu
criteria
state
condit
must
met
satisfi
criteria
least
two
serial
rtpcr
must
neg
rna
swab
must
nasopharyng
collect
assay
must
space
hour
patient
must
remain
apyrex
least
hr
without
antipyret
medic
use
resolut
respiratori
sign
symptom
minimum
seven
day
pass
sinc
preliminari
symptom
appear
prevent
strategi
selfprotect
hand
wash
least
second
visit
public
space
soap
hand
sanit
least
ethanol
recommend
also
recommend
avoid
touch
denot
facial
tzone
eye
nose
mouth
access
point
virion
upper
respiratori
tract
avoid
contact
peopl
alreadi
present
symptom
well
avoid
gather
crowd
place
travel
outbreak
area
must
prohibit
healthi
individu
must
maintain
least
six
feet
distanc
individu
present
symptom
steril
frequent
handl
surfac
benefici
healthcar
worker
manag
patient
requir
full
person
protect
equip
ppe
contain
surgic
mask
doubl
glove
fullsleev
procedur
gown
eye
shield
mask
prevent
droplet
enter
mask
must
exclus
dawn
prior
perform
procedur
associ
higher
risk
aerosol
exposur
tracheostomi
tracheal
intub
bronchoscopi
cardiopulmonari
resuscit
cpr
noninvas
ventil
niv
procedur
potenti
aerosol
viru
contain
commun
transmiss
achiev
closur
educ
institut
busi
airspac
sport
event
highrisk
individu
older
chronic
comorbid
without
symptom
also
requir
selfquarantin
decreas
likelihood
contract
herd
protect
develop
symptom
potenti
patient
remain
quarantin
selfisol
away
separ
room
separ
bathroom
least
day
selfisol
must
extend
pet
well
record
case
humantodog
transmiss
concern
immedi
contact
public
health
hotlin
gener
practic
clinic
via
telemedicin
must
establish
attain
potenti
diagnosi
face
mask
need
patient
prevent
droplet
spread
role
vitamin
vitamin
c
vitamin
c
lascorb
acid
pleiotrop
physiolog
role
evid
support
protect
effect
high
dose
intraven
vitamin
c
hdivc
sepsisinduc
ard
vitamin
c
reinforc
mainten
alveolar
epitheli
barrier
transcript
upregul
protein
channel
cftr
enac
nak
atpas
regul
alveolar
fluid
clearanc
hdivc
implic
reduc
plasma
cellfre
dna
form
neutrophil
extracellular
trap
net
facilit
system
inflamm
sepsisinduc
multiorgan
failur
interestingli
elev
level
plasma
correl
increas
mortal
sever
sepsi
ard
endotheli
glycocalyx
reduc
significantli
hdivc
februari
random
control
trial
rct
undertaken
zhongnan
hospit
aim
evalu
clinic
efficaci
safeti
vitamin
c
viral
pneumonia
hypothes
vitamin
c
infus
improv
prognosi
sever
acut
respiratori
tract
infect
treatment
arm
includ
g
vitamin
c
infus
seven
day
primari
outcom
measur
ventilationfre
day
estim
complet
time
septemb
vitamin
vitamin
known
mitig
scope
acquir
immun
regener
endotheli
line
may
benefici
minim
alveolar
damag
caus
ard
level
evid
n
show
overal
protect
effect
vitamin
supplement
bacteri
viral
acut
respiratori
tract
infect
adjust
od
p
protect
effect
increas
individu
daili
weekli
regimen
vitamin
compar
dose
monthli
bolu
vitamin
adjust
od
p
furthermor
protect
effect
vitamin
defici
correct
supplement
adjust
od
p
result
pertin
major
individu
resid
northern
latitud
experi
vitamin
defici
serum
nmoll
due
extend
period
lack
sunlight
vaccin
unfortun
approv
vaccin
march
one
lead
candid
vaccin
manufactur
modernatx
inc
cambridg
usa
encapsul
within
lipid
nanoparticl
encod
fulllength
prefus
stabil
spike
glycoprotein
viru
vaccin
current
phase
openlabel
doserang
clinic
trial
evalu
safeti
profil
reactogen
immunogen
healthi
subject
estim
complet
time
june
novel
therapeut
current
multipl
avenu
therapi
explor
summar
promin
candid
remdesivir
remdesivir
nucleosid
inhibitor
strongest
candid
treatment
remdesivir
monophosphoramid
prodrug
caus
prematur
termin
viral
rna
replic
origin
develop
ebola
merscov
sarscov
furthermor
vitro
studi
human
cell
line
human
liver
cancer
cell
show
potent
interfer
remdesivir
polymeras
despit
intact
exon
proofread
activ
eight
clinic
trial
current
underway
china
franc
usa
suggest
dose
cours
iv
mg
first
day
iv
mg
nine
follow
day
lopinavir
ritonavir
proteas
inhibitor
lopinavir
ritonavir
combin
usual
part
haart
regimen
treat
hiv
lopinavir
ritonavir
combin
also
shown
effect
sar
vitro
current
chines
guidelin
treatment
includ
po
mg
dose
bid
durat
day
lopinavir
ritonavir
use
regimen
singleag
combin
either
ribavirin
current
rct
chines
clinic
trial
regist
number
chictr
patient
wuhan
aim
evalu
safeti
efficaci
lopinavir
ritonavir
regimen
sever
patient
twoarm
studi
compar
lopinavirritonavir
n
standard
care
n
statist
signific
differ
time
clinic
improv
two
group
day
result
statist
signific
day
mortal
day
reduc
length
stay
icu
reduc
five
day
lopinavirritonavir
treatment
clinic
trial
current
underway
south
korea
thailand
china
umifenovir
umifenovir
nonnucleosid
broadspectrum
antivir
licens
influenza
treatment
prophylaxi
russia
china
receiv
fda
approv
yet
umifenovir
membran
fusion
inhibitor
current
regimen
umifenovir
use
china
includ
po
dose
mg
td
durat
day
one
larg
chines
rct
aim
evalu
safeti
efficaci
combin
treatment
umifenovir
immunostimulatori
recombin
cytokin
genederiv
protein
anoth
chines
rct
aim
evalu
safeti
efficaci
singleag
treatment
umifenovir
chloroquin
chloroquin
antimalari
medic
virus
chloroquin
inhibit
phdepend
stage
replic
furthermor
chloroquin
immunomodul
depend
suppress
cytokin
product
dissemin
moreov
experi
monkey
cell
line
vero
show
chloroquin
interfer
receptor
glycosyl
therebi
affect
entri
mechan
treatment
especi
success
vitro
experi
infect
human
cell
line
human
liver
cancer
cell
interestingli
pharmacolog
model
util
dose
anoth
vitro
studi
show
hydroxychloroquin
higher
potenc
chloroquin
inhibit
infect
suggest
dose
studi
po
hydroxychloroquin
mg
bid
first
day
mg
bid
follow
four
day
secondari
rate
minim
preexposur
prophylaxi
postexposur
prophylaxi
individu
document
exposur
therefor
hydroxychloroquin
hypothes
adequ
chemoprophylaxi
candid
reduc
secondari
six
clinic
trial
current
underway
mexico
south
korea
china
spain
norway
usa
first
chines
studi
shown
posit
outcom
preliminari
data
although
sampl
size
small
n
still
promis
current
chines
guidelin
recommend
dose
chloroquin
po
mg
mg
chloroquin
phosphat
bid
durat
day
ace
inhibitor
acei
angiotensin
blocker
arb
enter
type
ii
pneumocyt
via
receptor
also
function
receptor
function
role
receptor
reciproc
physiolog
action
convert
angiotensin
ii
back
angiotensin
therefor
patient
take
arb
increas
plasma
level
angiotensin
ii
contrastingli
patient
take
acei
low
level
angiotensin
ii
upregul
receptor
kidney
heart
respons
acei
arb
dose
rat
human
data
avail
effect
alveolar
tissu
similar
upregul
receptor
heighten
infect
along
subsequ
clinic
ill
sever
discontinu
acei
arb
recommend
yet
hypertens
acut
risk
discontinu
exacerb
clinic
cours
increas
mortal
infect
view
discontinu
acei
arb
support
council
hypertens
european
societi
cardiolog
antipyret
ibuprofen
shown
upregul
receptor
current
evid
indic
ibuprofen
worsen
clinic
cours
current
standpoint
continu
use
ibuprofen
antipyret
agent
firstlin
antipyret
remain
acetaminophen
system
corticosteroid
use
system
corticosteroid
glucocorticoid
manag
ard
secondari
viral
pneumonia
controversi
rational
behind
approach
corticosteroid
prolong
viral
shed
time
maintain
system
antiinflammatori
state
minim
precipit
ard
dyspnea
sever
pneumonia
state
use
corticosteroid
recommend
outsid
clinic
trial
otherwis
indic
moreov
mer
patient
receiv
system
corticosteroid
higher
likelihood
receiv
invas
mechan
ventil
rais
mortal
rate
day
pandem
remind
volatil
ongo
plan
manag
primari
secondari
infect
plan
improv
accur
model
current
data
elimin
misinform
era
data
surplu
addit
variabl
strengthen
countermeasur
pandem
rapidli
updat
surveil
data
avail
robust
accredit
inform
multidisciplinari
approach
bridg
gap
knowledg
basic
scienc
clinic
scienc
literatur
review
comprehens
summar
relev
studi
relat
individu
paramet
influenc
clinic
cours
manag
due
lack
avail
valid
therapeut
countermeasur
reli
usag
public
health
contain
quarantin
approach
primari
learn
point
pandem
upheld
transpar
prevent
delay
threat
identif
secondli
delay
travel
restrict
selfquarantin
measur
led
logarithm
expans
case
lastli
need
increas
invest
toward
research
develop
